Ascom appoints David Hale as new CEO

On December 9, 2025, Ascom Holding AG announced the appointment of David Hale as the new CEO of the Ascom Group, effective February 4, 2026. Hale succeeds Michael Reitermann, who has served as interim CEO and will remain an ordinary member of the Board of Directors. With over 25 years of international experience in the medical device and pharmaceutical sectors, Hale brings a wealth of knowledge and proven leadership skills to the role.

Hale's notable career includes five years as CEO of the Guerbet Group in France, where he drove significant advancements in the company's leadership and market position. His previous roles at General Electric (GE) further accentuate his strong credentials, having managed global product portfolios and spearheaded digital transformation initiatives at GE Healthcare Digital in the U.S. and GE Healthcare Diagnostic Imaging in France. His dual American and French citizenship complements his international perspective.

The Chairman of the Board, Dr. Valentin Chapero, expressed confidence in Hale’s abilities, noting that his leadership and experience in complex markets align well with Ascom's strategic objectives. In his statement, Hale expressed gratitude for the appointment and excitement about returning to Ascom, where he began his career in Bern in 1991. He emphasized his commitment to working with Ascom's dedicated teams to develop impactful solutions that enhance data utilization.

Additionally, the Board of Directors acknowledged Michael Reitermann's contributions during his tenure as interim CEO, expressing sincere appreciation for his leadership and ongoing support as he transitions back to an ordinary Board member role. This leadership change is expected to guide Ascom towards its future growth and innovation goals.

The appointment of David Hale as the new CEO of Ascom Holding AG marks a pivotal moment in the company’s corporate landscape. With over 25 years of international leadership experience in the medical device and pharmaceutical sectors, Hale's tenure at the helm brings substantial expertise to Ascom, positioning it favorably for future growth within the technology landscape.

Investors should view this transition as a positive signal, particularly due to Hale's strong background in digital transformation and product portfolio management, particularly during his leadership at Guerbet Group and GE Healthcare. His experience in navigating complex markets could well serve Ascom's strategic priorities, especially as the company seeks to enhance its digital solutions within healthcare. Moreover, Hale’s dual citizenship could facilitate a broader understanding of European and American market dynamics, further strengthening Ascom’s operational strategy across these key territories.

As the CEO, Hale’s emphasis on collaboration with skilled teams will be essential. His stated intention to develop effective solutions that “bring data to life” resonates with the current demand for advanced healthcare technology and data analytics integration. This strategic focus may result in enhancing Ascom’s product offerings and thereby driving revenue growth.

However, while the leadership change presents opportunities, investors should remain cautious. Continuity is partially maintained with Michael Reitermann continuing as a board member, but the effectiveness of the transition will depend on the unified direction of the leadership team.

In conclusion, investors should closely monitor Ascom’s strategic initiatives under Hale’s guidance and assess how these align with broader industry trends. A vigilant approach will be prudent to accommodate any market fluctuations that may arise from this leadership transition, noting that stability often fosters investor confidence in technological advancements.